HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis

Leukemia

Volumn 16, Issue 4, 2002, Pages 508-519

  Wong, W W L ^a   Dimitroulakos, J ^a   Minden, M D ^a   Penn, L Z ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Apoptosis; Bcl 2; Geranylgeranylation; HMG CoA reductase; Statins

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; CARMUSTINE; CERIVASTATIN; CHOLESTEROL; DOXORUBICIN; FARNESYL DIPHOSPHATE; FARNESYL TRANS TRANSFERASE; FLUINDOSTATIN; FLUOROURACIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; PROTEIN BCL 2; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUINONE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ASTROCYTOMA; CANCER CELL; CARCINOGENESIS; CELL TRANSFORMATION; COLON CANCER; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LUNG CANCER; MELANOMA; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHABDOMYOLYSIS; TUMOR CLASSIFICATION;

EID: 0036239832     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402476     Document Type: Review

References (170)

1. Apoptosis and therapy
2. Apoptosis in cancer: Cause and cure
3. Apoptosis modulators as cancer therapeutics
4. Receptor and mitochondrial-mediated apoptosis in acute leukemia - A translational review
5. Biochemical pathways of caspase activation during apoptosis
6. Apoptosis control by death and decoy receptors
7. Bcl-2 family proteins
8. A matter of life and cell death
9. BCL-2 family members and the mitochondria in apoptosis
10. Cell suicide for beginners
11. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis
12. The hallmarks of cancer
13. Induction of apoptosis by cancer chemotherapy
14. Regulation of the mevalonate pathway
15. Cholesterol biosynthesis and metabolism
16. Biosynthesis of ubiquinone
17. Recent advances in the study of prenylated proteins
18. Relationships among dolichyl phosphate, glycoprotein synthesis, and cell culture growth
19. Current and future treatment of hyperlipidemia: The role of statins
20. Pro and con: Low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management
21. Safety profiles for the HMG-CoA reductase inhibitors: Treatment and trust
22. HMG-CoA reductase inhibitors
23. Cholesterol inhibition, cancer, and chemotherapy
24. HMG-CoA reductase inhibitors: Role in normal and malignant cells
25. Isoprenoid-mediated inhibition of mevalonate synthesis: Potential application to cancer
26. Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: Possible mechanism for alteration of cholesterol biosynthesis
27. In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: Increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma
28. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells
29. Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor
30. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells
31. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549
32. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study
33. Lovastatin 5-year safety and efficacy study
34. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice
35. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice
36. Pharmacology of competitive inhibitors of HMG-CoA reductase
37. Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: A multicentre, randomized, double-blind, placebo-controlled study
38. Novel lipid-regulating drugs
39. Comparative tolerability of the HMG-CoA reductase inhibitors
40. Lovastatin
41. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia
42. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease
43. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia
44. Atorvastatin: A hydroxymethylglutaryl-coenzyme A reductase inhibitor
45. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
46. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
47. NK-104: A novel synthetic HMG-CoA reductase inhibitor
48. Crystal structure of the catalytic portion of human HMG-CoA reductase: Insights into regulation of activity and catalysis
49. Structural mechanism for statin inhibition of HMG-CoA reductase
50. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4
51. Clinical pharmacokinetics and practical applications of simvastatin
52. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
53. Clinical pharmacokinetics of cerivastatin
54. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor
55. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolism-monograph for physicians
56. Biosynthesis and characterization of (S)- and (R)-3-hydroxy-3-methylglutaryl coenzyme A
57. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
58. A receptor-mediated pathway for cholesterol homeostasis
59. HMG-CoA reductase inhibitors and myotoxicity
60. HMG-CoA reductase inhibitors and P-glycoprotein modulation
61. Rhabdomyolysis and renal failure associated with cerivastatin- gemfibrozil combination therapy
62. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein
63. Atorvastatin transport in the Caco-2 cell model: Contributions of P- glycoprotein and the proton-monocarboxylic acid co-transporter
64. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial
65. 3A4
66. Drug firm withdraws statin from the market
67. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin
68. Cell cycle-specific effects of lovastatin
69. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion
70. A cell cycle-regulated inhibitor of cyclin-dependent kinases
71. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2
72. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells
73. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53
74. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase
75. Lovastatin and simvastatin are modulators of the proteasome
76. A highly conserved signal controls degradation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in eukaryotes
77. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study
78. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes
79. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications
80. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells
81. Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin
82. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach
83. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro
84. Lovastatin induces apoptosis in malignant mesothelioma cells
85. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis
86. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells
87. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells
88. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
89. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line
90. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death
91. Lovastatin induces apoptosis in metastatic ovarian cell line
92. Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis
93. Lovastatin induces apoptosis in a primitive neuroectoectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint
94. Lack of correlation between 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and lovastatin resistance in nerve growth factor treated PC-12 cells
95. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin
96. In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor
97. Amplification of the gene for 3-hydroxy-3-methylglutaryl coenzyme A reductase, but not for the 53-kDa protein, in UT-1 cells
98. Impaired regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation in lovastatin-resistant cells
99. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells
100. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells
101. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells
102. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac
103. Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines
104. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells
105. The sensitivity of leukemic bone marrow to simvastatin is lost at remission: A potential purging agent for autologous bone marrow transplantation
106. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors
107. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice
108. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
109. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
110. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme
111. II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma
112. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias
113. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells
114. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells
115. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells
116. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
117. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis
118. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis
119. Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma
120. Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma
121. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation
122. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor
123. Inhibition of cell growth by lovastatin is independent of ras function
124. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice
125. Lovastatin inhibits in vivo tumour growth of H-ras and c-myc but not v-src oncogene-transformed cells
126. Induction of apoptosis in fibroblasts by c-myc protein
127. Effects of lovastatin on a human myeloma cell line: Increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein
128. Human multidrug-resistant (MRP,p190) myeloid leukemia HL-60/ADR cells in vitro: Resistance to the mevalonate pathway inhibitor lovastatin
129. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin
130. p53 is required for radiation-induced apoptosis in mouse thymocytes
131. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors
132. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mono-nuclear cells
133. Statins as a newly recognized type of immunomodulator
134. Statins inhibit leukocyte recruitment: New evidence for their anti- inflammatory properties
135. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products
136. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
137. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors block calcium-dependent tyrosine kinase Pyk2 activation by angiotensin II in vascular endothelial cells. Involvement of geranylgeranylation of small G protein Rap1
138. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor
139. Pleiotropic effects of statins: Do they matter?
140. Inhibiting geranyl-geranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells
141. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types
142. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
143. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the Pl 3-kinase/Akt pathway
144. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells
145. Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells
146. 17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation
147. Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors
148. Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-1 receptors in human fibroblasts
149. Effect of pravastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on survival of AH130 hepatoma-bearing rats
150. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin
151. Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin
152. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
153. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice
154. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis
155. Synergistic anti-tumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice
156. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells
157. Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta- interferon on human glioma cells
158. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines
159. Interaction of cytosine arabinoside and lovastatin in human leukemia cells
160. Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells
161. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia
162. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation
163. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
164. Activation of the cholesterol pathway and Ras maturation in response to stress